← Back to Search


G1899 Korean Red Ginseng Extract Powder 120 mg/tablet for Vasodilation

Led By Amir H.S. Rafie, MD
Research Sponsored by Korea Ginseng Corporation
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Able to swallow tablets whole
Healthy adults (male and female) who are 20 to 75 years of age (inclusive)
Screening 3 weeks
Treatment Varies
Follow Up 12 weeks
Awards & highlights

Study Summary

This trial aims to find out if the TP has any effect on blood flow and platelet aggregation, and if it is beneficial for cardiovascular health. It also wants to understand if the TP is safe and

Who is the study for?
This trial is for healthy adults interested in the potential cardiovascular benefits of Korean Red Ginseng. Participants should not have any current heart conditions or high blood pressure and must be willing to take either a placebo or ginseng tablets.Check my eligibility
What is being tested?
The study tests if Korean Red Ginseng Extract improves blood flow and reduces platelet aggregation compared to a placebo. It also examines its effects on overall cardiovascular health. There are two doses being tested: one with 120 mg/tablets and another with 500 mg/tablets.See study design
What are the potential side effects?
Possible side effects may include digestive discomfort, headaches, sleep problems, allergic reactions, or changes in blood pressure. However, as this trial is assessing safety too, exact side effects will be monitored closely.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
I can swallow pills without any issues.
I am a healthy adult aged between 20 and 75.


Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Blood Flow
Platelet Aggregation
Secondary outcome measures
Adverse Events
Augmentation Index
Blood Coagulation assessed by Activated Partial Thromboplastin Time (aPTT)
+52 more

Trial Design

3Treatment groups
Active Control
Placebo Group
Group I: G1899 Korean Red Ginseng Extract Powder 120 mg/tabletActive Control1 Intervention
480 mg of Korean Red Ginseng Extract powder per day for a total of 12 weeks.
Group II: G1899 Korean Red Ginseng Extract Powder 500 mg/tabletActive Control1 Intervention
2000 mg of Korean Red Ginseng Extract Powder per day for a total of 12 weeks.
Group III: PlaceboPlacebo Group1 Intervention
Inactive Ingredients

Find a Location

Who is running the clinical trial?

Korea Ginseng CorporationLead Sponsor
4 Previous Clinical Trials
1,536 Total Patients Enrolled
Nutrasource Pharmaceutical and Nutraceutical Services, Inc.NETWORK
32 Previous Clinical Trials
1,793 Total Patients Enrolled
Amir H.S. Rafie, MDPrincipal InvestigatorValiance Clinical Research

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals above the age of 20 eligible to participate in this ongoing medical study?

"Prospective participants for this study must be within the age range of 20 and 75 years old, with an upper limit on their eligibility."

Answered by AI

What is the current number of participants enrolled in this clinical study?

"Indeed, the information found on clinicaltrials.gov confirms that this particular trial is actively seeking participants. The study was first posted on January 1st, 2024 and recently updated on January 31st, 2024. The research team aims to recruit a total of 120 patients from a single designated site."

Answered by AI

Are there any available openings for patients to participate in this medical study?

"Indeed, as per clinicaltrials.gov, this study is currently in the recruitment phase. The trial was first posted on January 1st, 2024 and underwent its latest revision on January 31st, 2024."

Answered by AI

What are the primary objectives of this scientific study?

"The primary objective of this study, to be evaluated over a period of approximately 12 weeks, is to measure platelet aggregation. Secondary outcomes include assessing blood coagulation through prothrombin time (PT), measuring the change from baseline to 12 weeks in PT for both placebo and test products. Additionally, systolic blood pressure (SBP) at rest will be assessed by comparing the change from baseline to 6 weeks in SBP levels while seated and supine between placebo and test products. Lastly, changes in heart rate (beats per minute) will also be monitored from baseline throughout the study."

Answered by AI

Is it possible for me to enroll as a participant in this clinical trial?

"Applicants who are between the ages of 20 and 75 and have a documented history of cardiovascular disease are eligible for enrollment in this clinical trial. The study aims to accept approximately 120 participants."

Answered by AI

Who else is applying?

What site did they apply to?
Valiance Clinical Research
What portion of applicants met pre-screening criteria?
Met criteria
~60 spots leftby Aug 2024